Join to access to all OVN content. Join for Free
The ART of breaking out of your comfort zone
Introversion in MSL overcoming fear in medical science building a personal brand in healthcare networking for introverts success strategies for MSLs

The ART of breaking out of your comfort zone


Share This Article


Summary

In this episode, Cathy Andorfer joins Tom Caravela to discuss the unique challenges and advantages that introverts face within the medical science liaison (MSL) role. They explore the science behind introversion and extroversion, emphasizing the importance of overcoming fear and developing resilience. Cathy shares personal experiences and insights from her upcoming book, offering advice on goal setting, networking, and the significance of building a personal brand while staying authentic. The conversation wraps up with year-end reflections and the importance of being present in one's current role. The episode concludes with closing remarks, future episode teasers, and a reminder to subscribe.

Cathy Andorfer, US Field Medical Dermatology Lead at Bristol Myers Squibb discusses the art of breaking out of your comfort zone

Cathy shares…

👉 The difference between an introvert and an extrovert

👉 How introverts can find success in Medical Affairs

👉 Advice for extroverts on improved engagement

👉 Tips on how to do things that may terrify you

👉 Why “reflection” is so important and how to use it

Click for Source
Introversion in MSL, overcoming fear in medical science, building a personal brand in healthcare, networking for introverts, success strategies for MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN